Racial/ethnic disparities in timely receipt of buprenorphine among Medicare disability beneficiaries
- PMID: 37748421
- PMCID: PMC10615876
- DOI: 10.1016/j.drugalcdep.2023.110963
Racial/ethnic disparities in timely receipt of buprenorphine among Medicare disability beneficiaries
Abstract
Background: Medicare disability beneficiaries (MDBs) have disproportionately high risk of opioid use disorder (OUD) and related harms given high rates of comorbidities and high-dose opioid prescribing. Despite this increased risk, little is known about timely receipt of medication for opioid use disorder (MOUD), including potential disparities by patient race/ethnicity or moderation by county-level characteristics.
Methods: National Medicare claims for a sample of MDBs with incident OUD diagnosis between March 2016 and June 2019 were linked with county-level data. Multivariable mixed effects Cox proportional hazards models estimated time (in days) to buprenorphine receipt within 180 days of incident OUD diagnosis. Primary exposures included individual-level race/ethnicity and county-level buprenorphine prescriber availability, percent non-Hispanic white (NHW) residents, and Social Deprivation Index (SDI) score.
Results: The sample (n=233,079) was predominantly White (72.3%), ≥45 years old (76.3%), and male (54.8%). Black (adjusted hazard ratio [aHR]=0.50; 95% CI, 0.47-0.54), Asian/Pacific Islander (aHR=0.54; 95% CI, 0.41-0.72), Hispanic/Latinx (aHR=0.81; 95% CI, 0.76-0.87), and Other racial/ethnic groups (aHR=0.75; 95% CI, 0.58-0.97) had a lower likelihood of timely buprenorphine than non-Hispanic white beneficiaries after adjusting for individual and county-level confounders. Timely buprenorphine receipt was positively associated with county-level buprenorphine prescriber availability (aHR=1.05; 95% CI, 1.04-1.07), percent non-Hispanic white residents (aHR=1.01; 95% CI, 1.00-1.01), and SDI (aHR=1.06; 95% CI, 1.01-1.10).
Conclusions: Racial/ethnic disparities highlight the need to improve access to care for underserved groups. Implementing equity-focused quality and performance measures and developing interventions to increase office-based buprenorphine prescribing in predominantly minority race/ethnicity counties may reduce disparities in timely access to medication for OUD.
Keywords: Buprenorphine; Community characteristics; Disparities; Medicare disability beneficiaries; Opioid use disorder.
Copyright © 2023. Published by Elsevier B.V.
Conflict of interest statement
Declaration of Competing Interest Dr. Samples reported receiving consulting fees from the American Society of Addiction Medicine outside the submitted work. Drs. Miles, Nyaku, Gupta, Simon, Crystal and Mr. Treitler and Mr. Hermida do not report any conflicts of interest.
Similar articles
-
Racial and ethnic disparities in medication for opioid use disorder access, use, and treatment outcomes in Medicare.J Subst Use Addict Treat. 2024 Feb;157:209271. doi: 10.1016/j.josat.2023.209271. Epub 2023 Dec 21. J Subst Use Addict Treat. 2024. PMID: 38135120
-
Racial and Ethnic Inequities in Buprenorphine and Methadone Utilization Among Reproductive-Age Women with Opioid Use Disorder: an Analysis of Multi-state Medicaid Claims in the USA.J Gen Intern Med. 2023 Dec;38(16):3499-3508. doi: 10.1007/s11606-023-08306-0. Epub 2023 Jul 12. J Gen Intern Med. 2023. PMID: 37436568
-
Racial Inequality in Receipt of Medications for Opioid Use Disorder.N Engl J Med. 2023 May 11;388(19):1779-1789. doi: 10.1056/NEJMsa2212412. N Engl J Med. 2023. PMID: 37163624 Free PMC article.
-
Assessment of Racial and Ethnic Disparities in the Use of Medication to Treat Opioid Use Disorder Among Pregnant Women in Massachusetts.JAMA Netw Open. 2020 May 1;3(5):e205734. doi: 10.1001/jamanetworkopen.2020.5734. JAMA Netw Open. 2020. PMID: 32453384 Free PMC article.
-
Financial sustainability of payment models for office-based opioid treatment in outpatient clinics.Addict Sci Clin Pract. 2021 Jul 5;16(1):45. doi: 10.1186/s13722-021-00253-7. Addict Sci Clin Pract. 2021. PMID: 34225785 Free PMC article. Review.
References
-
- Abraham R, Wilkinson E, Jabbarpour Y, Petterson S, Bazemore A, 2020. Characteristics of office-based buprenorphine prescribers for Medicare patients. The Journal of the American Board of Family Medicine 33, 9–16. - PubMed
-
- Anderson JB, Martin SA, Gadomski A, Krupa N, Mullin D, Cahill A, Jenkins P, 2022. Project ECHO and primary care buprenorphine treatment for opioid use disorder: Implementation and clinical outcomes. Substance Abuse 43, 222–230. - PubMed
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Medical